Daihan Pharmaceutical Co.Ltd (023910) — Cash Flow Reinvestment Rate
Daihan Pharmaceutical Co.Ltd (023910) has a Cash Flow Reinvestment Rate of 1.44x as of September 2025, reinvesting ₩13.63 Billion (capex ₩10.79 Billion plus investments ₩-2.84 Billion) from operating cash flow of ₩9.47 Billion. Explore Daihan Pharmaceutical Co.Ltd capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Daihan Pharmaceutical Co.Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Daihan Pharmaceutical Co.Ltd across 11 annual periods. Also explore 023910 total asset value for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Daihan Pharmaceutical Co.Ltd. For live market cap and broader valuation context, see 023910 market cap.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.48x | ₩88.43 Billion | ₩35.64 Billion | ₩15.80 Billion | ▲ +145.5% |
| 2023 | 1.01x | ₩39.28 Billion | ₩38.86 Billion | ₩21.28 Billion | ▲ +232.5% |
| 2022 | 0.30x | ₩8.81 Billion | ₩29.00 Billion | ₩8.62 Billion | ▲ +1.7% |
| 2021 | 0.30x | ₩12.13 Billion | ₩40.62 Billion | ₩11.85 Billion | ▼ -8.3% |
| 2020 | 0.33x | ₩10.96 Billion | ₩33.63 Billion | ₩5.36 Billion | ▼ -53.7% |
| 2019 | 0.70x | ₩24.84 Billion | ₩35.26 Billion | ₩17.30 Billion | ▼ -33.8% |
| 2018 | 1.06x | ₩47.80 Billion | ₩44.94 Billion | ₩46.69 Billion | ▲ +2.3% |
| 2017 | 1.04x | ₩21.26 Billion | ₩20.45 Billion | ₩21.05 Billion | ▲ +18.5% |
| 2016 | 0.88x | ₩24.50 Billion | ₩27.92 Billion | ₩21.90 Billion | ▲ +290.5% |
| 2015 | 0.22x | ₩4.04 Billion | ₩17.98 Billion | ₩3.96 Billion | ▼ -82.1% |
| 2014 | 1.26x | ₩11.90 Billion | ₩9.48 Billion | ₩10.47 Billion | — |